Modulation of SUR1 $\text{K}_{\text{ATP}}$ Channel Subunit Activity in the Peripheral Nervous System Reduces Mechanical Hyperalgesia after Nerve Injury in Mice

Wing Luu 1, James Bjork 2, Erin Salo 1, Nicole Entenmann 1, Taylor Jurgenson 1, Cole Fisher 1 and Amanda H. Klein 1,*

1 Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, MN 55812, USA; luuxx075@d.umn.edu (W.L.); salox099@d.umn.edu (E.S.); enten002@d.umn.edu (N.E.); tjurgenson@gmail.com (T.J.); nfisher@d.umn.edu (C.F.)

2 Department of Biomedical Sciences, Medical School Duluth, Duluth, MN 55812, USA; jbjork1@d.umn.edu

* Correspondence: ahklein@d.umn.edu

Received: 22 March 2019; Accepted: 3 May 2019; Published: 7 May 2019

Abstract: The ATP-sensitive $\text{K}^+$ channel ($\text{K}_{\text{ATP}}$) is involved in hypersensitivity during chronic pain and is presumed to be a downstream target of mu opioid receptors. Multiple subtypes of $\text{K}_{\text{ATP}}$ channels exist in the peripheral and central nervous system and their activity may be inversely correlated to chronic pain phenotypes in rodents. In this study, we investigated the different $\text{K}_{\text{ATP}}$ channel subunits that could be involved in neuropathic pain in mice. In chronic pain models utilizing spinal nerve ligation, SUR1 and Kir6.2 subunits were found to be significantly downregulated in dorsal root ganglia and the spinal cord. Local or intrathecal administration of SUR1-$\text{K}_{\text{ATP}}$ channel subtype agonists resulted in analgesia after spinal nerve ligation but not SUR2 agonists. In ex-vivo nerve recordings, administration of the SUR1 agonist diazoxide to peripheral nerve terminals decreased mechanically evoked potentials. Genetic knockdown of SUR1 through an associated adenoviral strategy resulted in mechanical hyperalgesia but not thermal hyperalgesia compared to control mice. Behavioral data from neuropathic mice indicate that local reductions in SUR1-subtype $\text{K}_{\text{ATP}}$ channel activity can exacerbate neuropathic pain symptoms. Since neuropathic pain is of major clinical relevance, potassium channels present a target for analgesic therapies, especially since they are expressed in nociceptors and could play an essential role in regulating the excitability of neurons involved in pain-transmission.

Keywords: neuropathy; $\text{K}_{\text{ATP}}$ channels; SUR1; Kir6.2; analgesia; spinal nerve ligation

1. Introduction

Neuropathic pain is a common clinical problem encountered by many patients, especially those with diabetes, cancer, herpes zoster, nerve compression and various other conditions. It is estimated that neuropathic pain affects 6–8% of the general population, although this number has been suggested to be as high as 17% [1,2]. Neuropathic pain greatly decreases quality of life and the direct medical cost to patients can cost thousands of dollars [3]. Unfortunately, many currently available pharmaceuticals do not treat peripheral neuropathic pain effectively; therefore, the development of better treatment strategies is urgently required. One important group of ion channels needed to control and maintain neuronal excitability are potassium channels. The functional role of only a few potassium channels are known during chronic pain and increased activity of potassium channels within peripheral nociceptors or spinal cord pathways could provide pharmacological targets for new analgesics [4].

ATP-sensitive potassium ($\text{K}_{\text{ATP}}$) channels are inwardly rectifying potassium channels that couple metabolism to electrical activity of cells. $\text{K}_{\text{ATP}}$ channels are hetero-octamers composed of pore-forming
Kir6.1 or Kir6.2 subunits and sulfonylurea receptor (SUR1 or SUR2) regulatory subunits (4:4). These channels are widely expressed in most metabolically active tissues, including the nervous system [5]. Previous studies have found that agonists or downstream activation of $\text{K}_{\text{ATP}}$ channels have been implicated in the reduction of acute and chronic pain in rodent models of skin incision [6], formalin injection [7] and spinal nerve ligation [8]. Unfortunately, most studies have not closely investigated which $\text{K}_{\text{ATP}}$ channel subunits are contributing to the analgesic effects of these treatments or where these $\text{K}_{\text{ATP}}$ channels are located (e.g., spinal cord versus peripheral nervous system). Previous data suggest that Kir6.2/SUR1 is the predominant functional subtype within the peripheral nervous system but pain sensitization appears to be mediated mostly by SUR2 after cutaneous injury [9–14]. Current data are also lacking on $\text{K}_{\text{ATP}}$ channel expression changes occurring after initiation of chronic pain in the peripheral versus central nervous system over an extended (>30 days) period of time. This is important, as many animal models of chronic pain do not accurately reflect clinical pain syndromes due to the lack of time progression between injury and phenotypic assessment [15].

In this study, we show that $\text{Abcc8}$ (SUR1) and $\text{Kcnj11}$ (Kir6.2) gene expression is decreased in the dorsal root ganglia and sciatic nerves two months post spinal nerve ligation (SNL) in mice. Administration of SUR1-subtype $\text{K}_{\text{ATP}}$ channel agonists, by intraplantar or intrathecal injection, were able to alleviate mechanical hypersensitivity after SNL. Mice lacking the SUR1 $\text{K}_{\text{ATP}}$ channel subunits due to genetic modification, either by global knockout (SUR1 KO) or intrathecal injection of short hairpin RNA ($\text{Abcc8}$ shRNA), displayed mechanical hypersensitivity when compared to wild type and control mice. Taken together, these data suggest that $\text{K}_{\text{ATP}}$ channel expression and function make an important contribution to the development of neuropathic pain.

2. Results

2.1. Gene Expression of SUR1 and Kir6.2 Decreases in the Peripheral Nervous System after Spinal Nerve Ligation

It has been previously shown that different $\text{K}_{\text{ATP}}$ channel subunits are downregulated during chronic pain [9,12]. We attempted to confirm this by comparing the ipsilateral and contralateral dorsal root ganglia (DRG), sciatic nerves (SN) and spinal cords of mice after SNL. Expression of $\text{Abcc8}$ and $\text{Kcnj11}$ iso2 mRNA was significantly decreased in ipsilateral (i.e., injured) dorsal root ganglia versus contralateral (i.e., uninjured; Figure 1A,D). $\text{Abcc9}$ and $\text{Kcnj11}$ iso1 were also largely downregulated in ipsilateral DRG (Figure 1B,C), but were not statistically significant compared to contralateral DRG. For samples where matching ipsilateral and contralateral data were available, 70% of $\text{Abcc8}$ and nearly all $\text{Kcnj11}$ (100% for $\text{Kcnj11}$ iso1 and 88.9% for $\text{Kcnj11}$ iso2), the ipsilateral samples were lower than the contralateral DRG samples (Figure 1E). Similar data for $\text{Abcc}$ and $\text{Kcnj}$ subunits were also found in sciatic nerves (Figure 2A–D). In sciatic nerves, the number of ipsilateral samples for $\text{Abcc8}$ and $\text{Kcnj11}$ iso2 lower than the contralateral samples were 63.6% and 72.7%, respectively (Figure 2E). There were no significant expression differences across $\text{K}_{\text{ATP}}$ channel subunits in the spinal cord (Figure 3A–E). However, the number of spinal cord samples where $\text{Abcc8}$ and $\text{Kcnj11}$ iso2 were decreased in ipsilateral versus contralateral spinal cord were 81.8% and 100%, respectively (Figure 3F). $\text{Kcnj8}$ is not reported to be in the peripheral nervous system (PNS) [12] but the expression in the spinal cord was not altered after SNL (Figure 3E,F). Our own mRNA expression data also suggest that $\text{Kcnj8}$ is mostly expressed in the spinal cord and brainstem and is not expressed in cell bodies of peripheral nerves, including the dorsal root ganglia and trigeminal ganglia (Figure S1).
**Dorsal Root Ganglia**

![Graphs showing expression of KATP channel subunits in dorsal root ganglia](image)

**Figure 1.** Expression of K\(_{ATP}\) channel subunits in dorsal root ganglia are decreased after spinal nerve ligation (SNL). Relative expression of K\(_{ATP}\) channel subunits in ipsilateral (Ipsi) and contralateral (Contra) dorsal root ganglia >30 days post SNL. Relative gene expression for Abcc8 (protein: SUR1, A), Abcc9 (protein: SUR2, B), Kcnj11 iso1 (protein: Kir6.2, C) and Kcnj11 iso2 (protein: Kir6.2, D) compared against matching tissue expression for 18s. *p < 0.05 comparison between Ipsi vs. Contra. (E). Data in A–D are expressed as mean fold change (Ipsi/Contra) between matching samples.

**Sciatic Nerve**

![Graphs showing expression of KATP channel subunits in sciatic nerves](image)

**Figure 2.** Expression of K\(_{ATP}\) channel subunits in sciatic nerves are decreased after spinal nerve ligation (SNL). Relative expression of K\(_{ATP}\) channel subunits in ipsilateral (Ipsi) and contralateral (Contra) sciatic nerves >30 days post SNL. Relative gene expression for Abcc8 (protein: SUR1, A), Abcc9 (protein: SUR2, B), Kcnj11 iso1 (protein: Kir6.2, C) and Kcnj11 iso2 (protein: Kir6.2, D) compared against matching tissue expression for 18s. *p < 0.05 comparison between Ipsi vs. Contra. (E). Data in A–D are expressed as mean fold change (Ipsi/Contra) between matching samples.
was performed in behavioral experiments after intrathecal injection (Figure 6A–G). Intrathecal withdrawal testing were performed at several time points post injection to determine if reported
Although there were numerical decreases in mechanical thresholds after administration of tolbutamide (i.e., contralateral paw) did not show significant changes in force thresholds or latencies [16]. Intraplantar injection of SUR2 targeting K<sub>ATP</sub> channel agonists, including pinacidil, levcromakalim and nicorandil, did not significantly alter either thermal or mechanical withdrawal thresholds after intraplantar administration of K<sub>ATP</sub> channel agonists, particularly diazoxide, were apparent under both local and direct into the spinal subarachnoid space (i.e., intrathecal injection). Mechanical and thermal paw withdrawal testing were performed at several time points post injection to determine if reported analgesia by opening K<sub>ATP</sub> channels could be modality-specific. Intraplantar injection of SUR1 agonists, diazoxide and NN414, increased mechanical paw withdrawal thresholds in spinal nerve ligated mice (repeated measures ANOVA, F (5, 44) = 9.719, *p < 0.05, CI diazoxide = −2.999 to −0.9227, CI NN414 = −1.167 to −0.6546; Figure 4A,E) compared to vehicle treated mice (Figure 4L). Interestingly, thermal thresholds were not significantly increased after intraplantar administration of SUR1 agonists (Figure 4B,F). Intraplantar injection of SUR2 targeting K<sub>ATP</sub> channel agonists, including pinacidil, levcromakalim and nicorandil, did not significantly alter either thermal or mechanical withdrawal latencies/thresholds compared to vehicle (Figure 4C,D,G–J,M). Antagonists of SUR1/SUR2 subtype K<sub>ATP</sub> channels were also tested to see if mechanical and thermal sensitivity would be altered (Figure 5A–F). Although there were numerical decreases in mechanical thresholds after administration of tolbutamide and glyburide (Figure 5A,C), these were not significantly different compared to vehicle treatment (Figure 4L). Mechanical and thermal paw withdrawal thresholds collected from the un-injected paw (i.e., contralateral paw) did not show significant changes in force thresholds or latencies [16].

Since intraplantar administration of K<sub>ATP</sub> channel agonists appeared to alter mechanical sensitivity but do not appear to affect thermal sensitivity after SNL, only mechanical paw withdrawal testing was performed in behavioral experiments after intrathecal injection (Figure 6A–G). Intrathecal injection of SUR1 agonists, diazoxide and NN414, significantly increased mechanical paw withdrawal thresholds (repeated measures ANOVA, F (6, 56) = 32.94, *p < 0.05, CI diazoxide = −0.7470 to −0.4126, CI NN414 = −0.999 to −0.1607; Figure 6A,D) compared to vehicle (Figure 6G). Interestingly, the Kir6.2/SUR2 agonist levcromakalim also increased mechanical paw withdrawal thresholds after intrathecal injection (repeated measures ANOVA, CI levcromakalim = −3.363 to −1.969; Figure 6E). The analgesic effects of SUR1 agonists, particularly diazoxide, were apparent under both local and
agonists is most likely mediated through K<sub>ATP</sub> channels, as mice globally lacking the SUR1 subunit have minimal analgesia after intraplantar injection (Figure S2).

**Figure 4.** Paw withdrawal thresholds and latencies are increased after intraplantar administration of SUR1 agonists. Administration of the SUR1 agonist diazoxide (A) and the Kir6.2/SUR1 agonist NN-414 (E) significantly increased mechanical paw withdrawal thresholds compared to vehicle (L) (10 µL, hindpaw; repeated measures ANOVA, F (5, 44) = 9.719, * p < 0.05, repeated measures ANOVA, CI diazoxide = −2.999 to −0.9227, CI NN414 = −1.167 to −0.6546). Thermal latencies for diazoxide (B) and NN-414 (F) were not significantly different than vehicle (M). Mechanical and thermal thresholds for the SUR2 agonist pinacidil (C,D), the Kir6.2/SUR2 agonist levocromakalim (G,H) or the Kir6.2/SUR2B agonist nicorandil (I,J) were not significantly changed compared to vehicle (L,M). Error bars: SEM; n = 5–12/group.

**Figure 5.** Paw withdrawal thresholds and latencies do not change after intraplantar administration of K<sub>ATP</sub> channel antagonists. Administration of the SUR2 antagonist Tolbutamide (A,B), the SUR1 and SUR2 antagonist glyburide (C,D) or the SUR1 antagonist Gliclazide (E,F). Mechanical and thermal thresholds were not significantly changed compared to vehicle (Figure 4). Error bars: SEM; n = 4–10/group.
Diazoxide injection although these results were not found to be significantly significant. Diazoxide also decreased the amount of time spent immobile compared to vehicle in SNL animals, Figure 7E) and (2) average velocity (repeated measures ANOVA, F (2, 16) = 10.05, P < 0.05, Figure 7E) significantly increased paw withdrawal thresholds after intrathecal injection (Figure 6A-D) compared to vehicle (Figure 6G). Interestingly, the Kir6.2/SUR1 agonist NN-414 (D) or the Kir6.2/SUR2 agonist levcromakalim (E) significantly increased paw withdrawal thresholds compared to vehicle (G) (10 μL, hindpaw; * p < 0.05, repeated measures ANOVA, F (6, 56) = 32.94, * p < 0.05, CI diazoxide = −0.7470 to −0.4126, CI NN414 = −0.999 to −0.1607, CI levcromakalim = −3.363 to −1.969). Error bars: SEM; n = 5–10/group.

2.3. Local Diazoxide Administration Alters General Movement in Open Field Testing

In order to determine if SUR1 agonists can improve animal motility after SNL, we measured the mobility and activity of mice using an open field test. Since diazoxide had a robust effect on mechanical hypersensitivity within 30 min post intraplantar injection (Figure 4), we decided to measure any changes in overall activity compared to vehicle injection in SNL and uninjured mice. After intraplantar injection of vehicle in SNL animals, the distance traveled and average velocity decreased and the time spent immobile increased compared to baseline testing before injection (Figure 7). These data indicate that these animals are hypersensitive after intraplantar injection, which is consistent with previous reports and data collected during mechanical threshold testing (Figure 4L). Diazoxide injection attenuated the reduction in (1) distance traveled (repeated measures ANOVA, F (2, 16) = 10.05, p < 0.05, Figure 7E) and (2) average velocity (repeated measures ANOVA, F (2, 16) = 11.23, p < 0.05, Figure 7G). Diazoxide also decreased the amount of time spent immobile compared to vehicle in SNL animals, although these results were not found to be significantly significant.
2.4. Genetic Ablation or Knockdown of SUR1 Increases Mechanical Hypersensitivity

Previously, mice with a global deletion of SUR1 have been shown to exhibit impaired glucose tolerance and significantly more hypoglycemia when fasted than control animals [17] but to date, there has been no data reporting any somatosensory changes in SUR1 KO animals. Here, SUR1 knock out mice tested for mechanical and thermal sensitivity showed significantly decreased mechanical thresholds compared to wild type mice (ANOVA, F(2, 64) = 3.85, p = 0.026; Tukey post-hoc test; 95% CI = 0.097 to 1.58; Figure 8A). Mice data were pooled, since no significant differences were detected across sexes (ANOVA, F(1, 66) = 10.05, p = 0.002). Thermal thresholds were not altered in mice lacking SUR1 (Figure 8B).

Using a parallel strategy to impair SUR1 function specifically in the lumbar spinal cord and dorsal root ganglia, we introduced a shRNA via an adeno associated virus (AAV) to reduce Abcc8 mRNA by intrathecal injection. Mechanical thresholds were reduced two weeks post injection and remained lower for at least four weeks after inoculation (repeated measures ANOVA, F(2, 64) = 3.85, p = 0.026; Tukey post-hoc test; 95% CI = 0.097 to 1.58; Figure 9A). Thermal thresholds were not altered 4 weeks after Abcc8 shRNA administration (Figure 9B). Validation of viral inoculation was performed by fluorescence microscopy (Figure 9C) and reduction in Abcc8 mRNA expression was confirmed via quantitative PCR (qPCR). The mRNA expression of Abcc8 K\textsubscript{ATP} channel subunits was decreased in...
dorsal root ganglia, spinal cord (paired t-test, \( p = 0.0046 \)) and sciatic nerves (paired t-test, \( p = 0.045 \)) five weeks after intrathecal injection (Figure 9D–F). The mRNA levels of other \( K_{ATP} \) channel subunits (i.e., \( Abcc9, Kncj11 \) and \( Kcnj8 \)) were not significantly altered after \( Abcc8 \) shRNA inoculation (Figure S3).

![Figure 8](image)

**Figure 8.** Mechanical paw withdrawal thresholds but not thermal paw withdrawal thresholds are decreased in male and female SUR1 KO mice compared to WT mice. (A) Mechanical paw withdrawal thresholds are significantly decreased in SUR1KO mice compared to WT mice (ANOVA, F(2, 64) = 3.85, \( p = 0.026 \); Tukey post-hoc test; 95% CI = 0.097 to 1.58). (B) Thermal withdrawal latencies were not significantly different between genotypes. Data across sex and age of age are aggregated since no significant differences were found.

![Figure 9](image)

**Figure 9.** Intrathecal injection of \( Abcc8 \) shRNA decreases mechanical paw withdrawal latencies in mice. (A) Intrathecal injection of AAV9-GFP-U6-m-\( ABCC8 \)-shRNA (10 \( \mu \)L) significantly decreases mechanical paw withdrawal thresholds over time in mice compared to control injections (AAV9-GFP-U6-m-scramble-shRNA) (repeated measures ANOVA, F(3, 24) = 3.02, \( p = 0.049 \)). (B) Thermal paw withdrawals were not significantly changed four weeks post injection. (C) Histological images of dorsal root ganglia (DRG), spinal cord and sciatic nerve section from an animal after \( Abcc8 \) shRNA injection. Green fluorescent protein is detected in both primary afferent cell bodies and in the spinal cord after five weeks post injection. Images taken at 10x magnification. The mRNA expression of \( Abcc8 \) \( K_{ATP} \) channel subunits are decreased in (D) dorsal root ganglia, (E) spinal cord (paired t-test, \( p = 0.0046 \)) and (F) sciatic nerves (paired t-test, \( p = 0.045 \)), five weeks after intrathecal injection.

2.5. **Peripheral Application of SUR1 Subtype Agonists Decreased Evoked Mechanical Responses to Nerve Fibers Innervating the Hindpaw**

We performed ex-vivo recordings from the sural nerve because: (1) recordings could be obtained from a receptive field innervated by the ligated nerve; and (2) the sural nerve innervates the lateral plantar surface of the hind paw and overlaps with the skin region that is tested by our mechanical and thermal paw withdrawal assays. Application of SUR1 subtype agonists provided the greatest
analgesic effect during mechanical paw withdrawal, therefore the focus on the electrophysiology recordings was responsiveness to increasing mechanical force. This way we could directly compare our results from the mechanical paw withdrawal thresholds (Figures 4 and 5) with the electrophysiological recordings. Mechanical responses were re-tested 15–20 min after removal of the reservoir ring following drug washout and these responses were largely returned to baseline (≥50% reversal of drug-induced response change, data not shown). Many units exhibited a large amount of variability in their evoked responses before diazoxide and glyburide application. To draw valid conclusions about whether a change in response level after drug application was due to the action of drug or to normal response variability, we normalized the data to the mechanical responsiveness before drug application (“post-pre”). Figure 10A gives an example of a C-fiber response before (Figure 10A) and after (Figure 10B) diazoxide application. Overall, diazoxide decreased C-fiber responses to increasing mechanical stimulation in SNL mice (F (5,70) = 3.70, p = 0.025); Tukey post-hoc comparing 0.1 g versus 5 g and 8 g; 95% CI = 3.05 to 28.2 and 0.55 to 25.7, respectively; Figure 10C, n = 8/group). Glyburide application did not significantly change the number of action potentials across mechanical forces. We also did not find any significant changes in number of action potentials post drug application in A delta-fibers (Figure 10D, n = 4) or A beta-fibers (Figure 10E, n = 6), however for several myelinated fibers there was a numerical decrease in responsiveness to supra threshold stimuli.

**Figure 10.** The SUR1 agonist, diazoxide, decreases mechanical responsiveness of unmyelinated, C-fibers. (A) Increase in number (dots) and peak instantaneous frequency (left y-axis) of C-fiber action potentials as the force of stimulation is increased in a step-wise fashion (right y-axis). Inset: Example trace from recording. (B) Application of diazoxide (100 uM, 10 min) to the receptive field of a C-fiber decreases the number of action potentials compared to before application. (C) Diazoxide decreases C-fiber responses to increasing mechanical stimulation in SNL mice (F (5,70) = 3.70, p = 0.025); Tukey post-hoc comparing 0.1 g versus 5 g and 8 g; 95% CI = 3.05 to 28.2 and 0.55 to 25.7, respectively; n = 8/group). Glyburide application did not significantly change the number of action potentials across mechanical forces. No significant changes in number of action potentials post drug application were found in myelinated A delta-fibers (D) or A beta-fibers (E). Data presented as number of action potentials after drug application subtracted from the number of action potentials during the same time period before drug application.

3. Discussion

The present study investigated the loss of SUR1-subtype K\textsubscript{ATP} channels using a neuropathic pain model in mice. Intraplantar and intrathecal administration of SUR1-subtype agonists were beneficial for alleviating mechanical hypersensitivity and improve mobility after SNL. Administration
of diazoxide, a SUR1 agonist, decreased evoked sural nerve responses to suprathreshold mechanical stimulation. Genetic strategies confirmed that the loss of SUR1-subtype \( K_{\text{ATP}} \) channels contributes to mechanical hypersensitivity compared to control mice.

3.1. SUR1-Subtype \( K_{\text{ATP}} \) Channels Contribute to Analgesia in the Peripheral and Central Nervous System after Nerve Injury

Our qPCR data are largely in agreement with previous studies, indicating that \( K_{\text{ATP}} \) channel expression is decreased in DRG after nerve injury [12,18]. \( Abcc8 \) (SUR1) and \( Kcnj11 \) iso2 (Kir6.2) expression is significantly decreased in injured versus non-injured DRG (Figure 1) and similar changes were also seen in sciatic nerves. These results demonstrate that a loss of \( K_{\text{ATP}} \) channels appears to occur mostly in the peripheral nervous system, while loss in the spinal cord is less pronounced. The loss of \( Kcnj11 \) (Kir6.2) was also detected in DRG and the spinal cord but appears to be isoform specific, as \( Kcnj11 \) iso2 was much further decreased than \( Kcnj11 \) iso1. To date, there are two confirmed \( Kcnj11 \) isoforms in mice and humans. In our results, the second isoform is more robustly expressed in DRG than in the spinal cord and vice versa for the first isoform. It is unknown whether this baseline expression is similar between mice and humans or if changes seen after SNL in the mouse would be similar to humans.

Spinal nerve ligation in rats has been shown to decrease basal \( K_{\text{ATP}} \) activity in DRG and decrease opening probability after application of diazoxide, a SUR1-subtype \( K_{\text{ATP}} \) channel agonist [11]. In addition, diazoxide gradually enhanced, while glybenclamide inhibited, channel opening in SNL and control rat DRGs [11]. Our ex-vivo data are also in agreement with these previous findings—diazoxide decreased mechanical sensitivity to sural peripheral nerve fibers, whereas glyburide did not (Figure 10). Previous reports have indicated that \( K_{\text{ATP}} \) channel subunit expression is localized to different areas in the nervous system. For example, SUR1 is the predominant SUR subunit in DRG [12],Kir6.1 is expressed in the spinal cord but not in DRG and Kir6.2 is expressed in DRG but not the spinal cord [11,18]. Validation of these findings by immunohistochemistry and western blotting was attempted with current commercially available antibodies for SUR1 and SUR2 (NBP2-34077 and NBP1-84436 Novus Biologicals, sc-5789 and sc-25684 Santa Cruz Biotechnology); however, validation in SUR1 KO mice was unsuccessful (data not shown). Nonetheless, our mRNA expression data indicate that \( Abcc8 \) (SUR1) is highly expressed in DRG and trigeminal ganglia and \( Abcc9 \) (SUR2) is highly expressed in the spinal cord and brainstem (Supplemental Figure S1).

3.2. SUR1 Involvement in Mechanical Hypersensitivity after Spinal Nerve Ligation

Our behavioral data also indicate that application of SUR1-subtype agonists are effective analgesics after local or intrathecal injection (Figures 4 and 6). These changes were more apparent for mechanical threshold testing than for thermal paw withdrawal thresholds. These data are consistent with prior immunohistochemistry data indicating that SUR1 expression is decreased after SNL, especially in large myelinated fibers expressing NF200 [11,12]. Large neurons have been shown to be more likely to express \( K_{\text{ATP}} \) subunits, which might indicate a cell type-specific expression of \( K_{\text{ATP}} \) channels [9]. Mice lacking SUR1 displayed increased mechanosensitivity compared to their wild-type counterparts and genetic knockdown of SUR1 using AAV viral vectors also decreased mechanosensitivity compared to their control virus counterparts. These data collectively demonstrate that a loss of \( K_{\text{ATP}} \) channel activity is attributed to mechanical hypersensitivity. These data are particularly intriguing from a pharmaceutical perspective, as many individuals with neuropathic pain report mechanical hypersensitivity or mechanical allodynia [19]. The open field testing data indicated that application of \( K_{\text{ATP}} \) channel agonists to the periphery is able to increase behavioral activity after SNL but not in un-injured animals. These data are important, as increased locomotor activity are noted in rodent studies and with a neuronal gain-of-function mutation of Kir6.2 [20]. The ex-vivo recordings suggest that SUR1-targeting agonists were able to significantly decrease mechanically-evoked responses to C-fibers but not A delta-or A beta-fibers. A more detailed follow-up study could demonstrate if responsiveness to \( K_{\text{ATP}} \) channel agonists is dependent on...
subclasses of myelinated fibers [21]. Interestingly, the Kir6.2/SUR2 agonist, levcromakalim, also elicited a slight analgesic effect when delivered via hindpaw (Figure 4G) or intrathecally (Figure 6E). This data indicates that agonists that target vascular K\textsubscript{ATP} channels may enhance vasodilation and improve neuropathy symptoms as seen with other vasodilatory agents [22–24].

SUR1 expression is not restricted to the central or peripheral nervous system. Global deletion of SUR1 results in impaired glucose tolerance due to loss of beta cell activity in the pancreas [17]. Fed glucose levels were not found to be significantly different across genotypes in this study (data not shown), which is in agreement from previous studies but in contrast with others [25]. We conclude that any changes in blood glucose as a result of SUR1 global deletion are minimal and probably do not contribute to the behavioral phenotype found in behavioral assays. We can assume this, because the targeted deletion of Abcc8 using shRNA intrathecal injection also resulted in similar mechanical threshold findings, indicating that loss of SUR1 in the spinal cord and dorsal root ganglion are more likely responsible for this behavioral phenotype than changes in glucose metabolism. In the spinal cord, SUR1 has also been found to form stable co-association with TRPM4 channels, a monovalent cation channel that is sensitive to calcium [26]. These SUR1-regulated NCCa-ATP channels have been found to be involved in cerebral ischemia, traumatic brain injury, spinal cord injury and subarachnoid hemorrhage [27–29]. Although activation of SUR1 expressing K\textsubscript{ATP} channels may be beneficial for pain due to neuropathy or inflammation [30–32], pain due to hypoxia or edema of the central nervous system may respond negatively to these treatments. In addition to neurons, SUR1 subunits are found in central nervous system astrocytes [33], DRG satellite cells [12] and brain microglia [34]. Our current data do not segregate the contribution(s) of different cell types in the involvement of hyperalgesia after SNL; however, future studies could carefully dissect the role of neurons versus glia through cre-lox recombination or viral vector strategies utilizing different cell-type promotors in the nervous system.

In conclusion, our study provides further substantiated evidence that loss of K\textsubscript{ATP} channel expression can contribute to mechanical hypersensitivity seen during peripheral nerve injury. Specifically, changes in SUR1 and Kcnj11 K\textsubscript{ATP} channel subunit expression after SNL were largely found in the peripheral nervous system. These data suggest that the activity of SUR1—and possibly Kir6.2—are important for the development of mechanical hyperalgesia seen during peripheral neuropathies.

4. Material and Methods

4.1. Animals and Breeding

All experimental procedures involving animals were performed and approved in accordance with the University of Minnesota Institutional Animal Care and Use Committee guidelines. Adult C57Bl6 mice were obtained via Charles River (5–6 weeks old, Raleigh, NC, USA). SUR1 global knockout mice (SUR1 KO) were obtained from the laboratory of Dr. Joseph Bryan at the Pacific Northwest Research Institute (Seattle, WA, USA) as used in previous studies [17] and kept on a C57Bl6 background. Verification of genotype was done via DNA extraction from mouse tail biopsies by the “Hot Shot” method [35] and DNA amplification using Amplitaq Gold DNA Polymerase (ThermoFisher Scientific, Waltham, MA, USA). The presence of the SUR1 KO allele was confirmed using PCR with the following primer set: forward 5′- CTG TCC ATC TGC ACG AGA CT-3′ and reverse 5′- AGG TTG TTG GAG GTC AG -3′ yielding a KO band of 350 bp and a WT allele band of 524 bp [36]. The temperature and cycling protocols were repeated for 40 cycles as follows: 95 °C for 10 min, 94 °C for 30 s, 62 °C for 30 s and 72 °C for 45 s.

4.2. Spinal Nerve Ligation

To create the neuropathic pain model, spinal nerve ligation (SNL) was performed on adult C57Bl6 mice [37]. The SNL surgery was performed, as previously described, on mice under deep isoflurane anesthesia and was completed within 20 min [38]. Using aseptic technique, an incision over L5-S1 was made, the left L6 transverse process was partially removed and the left L5 nerve was isolated and transected (ipsilateral). The right spinal nerve was left intact as a control (contralateral).
4.3. Tissue Collection and RNA Extraction

Mice were anesthetized with 5% isoflurane in oxygen and decapitated. In C57Bl6 mice, SNL and un-injured mice, cerebral cortex (brain), brainstem, trigeminal ganglia, sciatic nerves and lumbar dorsal root ganglia and spinal cords (L3–L6 segments) were collected. All tissues were dissected and snap frozen in liquid nitrogen. Tissues were stored at −80 °C for long-term storage. RNA was purified from the frozen tissue samples using Trizol regent (Sigma-Aldrich, St. Louis, MO, USA). RNA was isolated using the RNeasy Mini Spin Columns (Qiagen, Germantown, MD, USA) with a DNase I treatment step. The quantity and quality of the eluted RNAs were assessed by Nanodrop spectrophotometry (Thermo Fisher Scientific) and/or Qubit fluorometric quantification (Thermo Fisher Scientific).

4.4. Quantitative PCR

Synthesis of cDNA from all purified RNA samples (50 ng) was performed using the Omniscript RT Kit and protocol from Qiagen. Primers were designed using sequences from NCBI primer design (Table 1). qPCR was performed with LightCycler 480 technology (Roche, Branchburg, NJ, USA) and SYBR Green I dye (Roche). Gene specific cDNA copy number was typically quantified against a ≥5 point, 10 fold serial dilution of gene specific cDNA standard in the range of 1e6 to 1e1 copies per reaction. The temperature and cycling protocol were as follows: 95 °C for 10 sec, 60 °C for 10 sec and 72 °C for 20 sec and was repeated for 45 cycles. Expression of a housekeeping gene, 18S, was used as an internal control. The presence of genomic DNA was assessed using negative RT-PCR controls. Relative expression levels of each gene of interest were determined by: (mean concentration)/(mean concentration of 18S), for each sample calculated using LightCycler® 480 Software. Two to three experimental replicates were performed for each sample.

| Gene  | Accession Number | Protein | Forward | Reverse |
|-------|------------------|---------|---------|---------|
| Abcc8 | NM_011510.3      | SUR1    | CCAACACGAGCCCTTGAACTT | AGTTGTTGCTGGAGGTCAG |
| Abcc9 | NM_011511.2      | SUR2    | TGTAGGCCAAGTGGGTTGTG | TCTGCTCGGTTGCTCAA |
| Kcnj11 iso1 | NM_010602.3 | Kir6.2 isoform 1 | CGCCCCAACAAGACCTCGAG | CCAGAGTGTTGCCCCATTG |
| Kcnj11 iso2 | NM_00124411.1 | Kir6.2 isoform 2 | ACCACGTTCATGGGCTACACC | TGGTCTTCAACCCCTCCC |
| Kcnj8 | NM_008428.5      | Kir6.1  | GCCACCATGGGAGAGAGTGG | CAAAACCGGTATGCCACAG |
| Rn18s | NR_003278.3      | 18s     | CGCCCCATAGGGGAAAATCTT | CAGITGGCAGTCTTTATGTC |

4.5. Evoked Behavioral Experiments

Mice were acclimatized to the testing platforms/arenas by placement in a transparent plastic box and were allowed to acclimate to the test chamber for at least 20 min. All behavioral tests were conducted in a blinded manner [39]. For mechanical studies, withdrawal latencies were assessed using a hand held electronic Von Frey hair (2392, IITC Life Sciences, Woodland Hills, CA, USA) on a wire mesh floor. Thermal latencies were assessed using a radiant paw withdrawal assay (390G, IITC Life Sciences, Woodland Hills, CA, USA) on a feedback controlled glass plate set to 30 °C. Positive responses included an abrupt flinching/withdrawal of the hind paw from the stimulus [40]. For baseline sensitivity, threshold measurements were run in at least triplicate on the left and right paw, with at least a 30 sec inter stimulus interval between paws. After drug injection, thresholds and latencies were measured on both paws 3, 15, 30, 45 and 60 min after administration. Behavioral tests in SNL animals were performed through postoperative day 14–60. Behavioral hypersensitivity to mechanical and thermal stimuli lasting 8 weeks or greater after nerve injury in rodents has been shown in previous studies [41–43]. Any animals that appeared to have altered baseline activity/responses in comparison to initial testing were removed from the study (less than 5% of animals).

4.6. Open Field Testing

Animals were placed in the center of a 40 cm × 40 cm open field arena and activity was recorded with a camcorder for offline analysis (HDR-CX405; Sony Corp., Tokyo, Japan). A digital light meter
was used to verify equal light distribution across the arena (50–60 lux). For baseline recordings, animals were allowed to explore for 15 min. After drug injection, animals were returned to the arena and allowed to explore for 30 additional minutes. The behavioral parameters were scored by the software Ethowatcher® (developed by the Laboratory of Comparative Neurophysiology of the Federal University of Santa Catarina, freely available on www.ethowatcher.ufsc.br, IEB-UFSC [44]), which translated recorded movement into numerical data for frame-by-frame analysis. Behavioral parameters for distance traveled, time spent immobile, average velocity and change in angular direction were compared across treatment groups.

4.7. Drug Delivery

Diazoxide, Pinacidil, NN-414, Nicorandil, Levromakalim (gift from Peter Dosa, Department of Medicinal Chemistry, University of Minnesota), Tolbutamide, Gliclazide and Glyburide (Sigma Aldrich or Tocris, Minneapolis, MN, USA) were initially diluted in DMSO and further diluted with saline to a final concentration of 10–100 uM in 5% DMSO in saline (vehicle). Compounds used in this study were used at concentrations found in previous behavioral studies [45–49]. Intraplantar injections were performed by gently restraining the animal in a Plexiglas restrainer or decapicone. A 27–33 gauge needle was inserted into the hindpaw skin at a 15–30° angle and 10 uL of solution was slowly delivered. A successful injection was determined when a small bleb was seen [50]. Intraperitoneal injections were delivered into the lower left abdominal quadrant using a 27 gauge needle at a volume of 100 µL. Intrathecal injections (10 µL) were performed by direct lumbar puncture in awake mice as previously described [51,52]. Most mice were tested with different chemicals, with at least 7 days between successive tests of active chemicals to avoid carryover effects.

4.8. shRNA Delivery

In order to achieve efficient and long-lasting knockdown of SUR1 K\textsubscript{ATP} channel subunits in the spinal cord and dorsal root ganglia, we utilized intrathecal injection of short hairpin (shRNA)-encoding AAV9 viral vectors [53]. The viral constructs AAV9-GFP-U6-m-ABCC8-shRNA and AAV9-GFP-U6-scramble-shRNA (shAAV-251792 and 7045, titer: 10^13 gc/mL, in PBS with 5% glycerol, Vector Biolabs, Malvern, PA, USA) were stored at −80 °C until injection. AAV9-viruses were injected intrathecally in awake mice as described previously [54–56] and behavioral assessments were performed one to four weeks post injection. Verification of mRNA knockdown was achieved using qPCR of harvested lumber spinal cords and dorsal root ganglia and sciatic nerves (see ‘Quantitative PCR’). Histological sections were taken from some animals in order to demonstrate that the delivery of AAV vectors within the lumbar intrathecal space leads to expression of green fluorescent protein (GFP) in spinal cord, DRGs and peripheral nerves. Sections (10 uM, Leica CM3050) were mounted onto electrostatically charged slides and images were collected using a Nikon TiS Microscope and associated software.

4.9. Ex-Vivo Electrophysiology

Mice were euthanized with 5% isoflurane in oxygen and cervical dislocation or decapitation. The hairy skin of the hind paw, together with the sural nerve, was carefully dissected and transferred to an in vitro system described previously [38,57]. The skin was mounted corium side up in an organ bath and superfused (10 mL/min) with synthetic interstitial fluid (SIF) heated to ~32 °C and continuously bubbled with 95% oxygen/5% carbon dioxide to obtain a SIF pH of 7.4. Under a microscope, the nerve was teased into smaller bundles that were placed onto a recording electrode to achieve single-fiber activity. After localizing the receptive field of the fiber with a glass probe, electrical stimuli was applied at the receptive field with a concentric electrode to calculate conduction velocity (CV). Fibers with a CV of less than 1 m/s were classified as C-fibers, those with a CV between 1 and 10 m/s were classified as A\textdelta-fibers and those with a CV more than 10 m/s were classified as A\textbeta-fibers [58]. Mechanical sensitivity was assessed by applying an ascending series of suprathreshold mechanical stimuli (0.1 to 8 g or 0.98 to 78.5 mN for 2 s, separated by 1 min) to the receptive field with a blunt probe (1-mm diameter)
connected to a computer-controlled mechanical stimulator (model 305C; Aurora Scientific, Aurora, ON, Canada) [59]. After baseline mechanical and thermal testing was completed, SIF within the ring was replaced by a 100 µM diazoxide or glyburide SIF solution, which was maintained for 5 min, followed by repeated mechanical stimulation. Action potentials were filtered, amplified, digitized and stored on a computer using DAPSYS, which was also used to control the mechanical stimulator and record bath temperature (Brian Turnquist, Bethel University, St. Paul, Minnesota; http://www.dapsys.net). The total number of evoked action potentials to the mechanical stimulus, including a post-stimulus period of 3 s, was used for data analysis pre- and post-drug application.

4.10. Statistical Analysis

We performed the appropriate t-test or one-way, two-way or repeated measures ANOVA followed by post hoc analysis (as indicated) to determine the significance of treatment groups for gene expression, mechanical and thermal paw withdrawals, open field testing parameters and ex-vivo single-unit recordings. All statistical analyses were carried out with Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA) or SPSS (Statistics 23, IBM, Chicago, IL, USA). The data are presented as means ± standard error and \( p < 0.05 \) was considered statistically significant.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2251/s1, Figure S1: Expression of \( K_{\text{ATP}} \) channel subunits in the nervous system of untreated C57Bl6 mice. Relative gene expression for \( Abcc8 \) (protein: SUR1, A), \( Abcc9 \) (protein: SUR2, B), \( Kcnj11 \) iso1 (protein: Kir6.2, C), \( Kcnj11 \) iso2 (protein: Kir6.2, D) and \( Kcnj8 \) (protein: Kir6.1) in the brain, brainstem (BS), spinal cord (SC), dorsal root ganglia (DRG) and trigeminal ganglia (TG) of mice (\( n = 4–11/\text{group} \)). Data are normalized to matching tissue expression for 18s. There are significantly different expression patterns of \( Kcnj \) and \( Abcc \) \( K_{\text{ATP}} \) channel subunits between tissue types. Higher expression of \( Kcnj11 \) iso1 versus \( Kcnj11 \) iso2 and \( Kcnj8 \) was found in the brain (\( F (8, 71) = 1.95, p = 0.046, \text{Tukey’s post hoc test} \)) and higher expression of \( Abcc8 \) versus \( Abcc9 \) in DRGs (\( F (4, 54) = 2.062, p = 0.038; \text{Sidak’s multiple comparisons test} \)). Figure S2: Paw withdrawal thresholds and latencies do not change after intraplantar administration of \( K_{\text{ATP}} \) channel agonists on SUR1 KO mice. Administration of the SUR1 agonist diazoxide (A), the SUR2 agonist pinacidil (B), the Kir6.2/SUR1 agonist NN-414 (C), the SUR1/SUR2 antagonist glyburide (D) or the SUR1 antagonist gliclazide (E) were not significantly changed compared to vehicle treatment (F). Error bars: SEM; \( n = 5–10/\text{group} \). Figure S3: Intrathecal injection of \( Abcc8 \) shRNA (10 \( \mu \text{L} \)) does not significantly decrease mRNA expression of non-SUR1 \( K_{\text{ATP}} \) channel subunits. mRNA expression for \( Abcc9 \) (A–C), \( Kcnj11 \) iso1 (D–F), \( Kcnj11 \) iso2 (G–I) or \( Kcnj8 \) (J) shown for dorsal root ganglia, spinal cords and sciatic nerves. Tissue collection performed five weeks after intrathecal injection.

Author Contributions: Conceptualization, A.H.K.; Methodology, J.A.B., A.H.K.; Formal Analysis, W.L., C.F., A.H.K.; Investigation, W.L., J.A.B., E.S., N.E., T.J., C.F., A.H.K.; Data Curation, W.L, C.F., A.H.K.; Writing—Original Conceptualization, A.H.K.; Methodology, J.A.B., A.H.K.; Formal Analysis, W.L, C.F., A.H.K.; Draft Preparation, A.H.K.; Writing—Review & Editing, J.A.B., C.F., A.H.K.; Visualization, A.H.K.; Supervision, A.H.K.; Project Administration, A.H.K.; Funding Acquisition, A.H.K.

Funding: Funding provided by the NIH to A.H.K. (K01 DA042902) and the University of Minnesota Duluth Undergraduate Research Opportunity Program to T.J.

Acknowledgments: The authors thank Peter Dosa, Department of Medicinal Chemistry, University of Minnesota, for the donation of the levcromakalim. The SUR1 global knock out mice were obtained from Joseph Bryan at the Pacific Northwest Diabetes Institute, Seattle, WA, USA. Brian Turnquist provided assistance regarding ex-vivo recordings and Dapsys implementation (Bethel University, St. Paul, MN, USA). Robert Meyer (Labortechnik Franken, Köthenbach, Germany) provided the thermocouple and adapter box for the ex-vivo recordings. Taryn Anderson (University of Minnesota Duluth) provided the microscopy images in Figure 9.

Conflicts of Interest: The authors do not have any conflicts of interest to report.

References

1. Van Hecke, O.; Austin, S.K.; Khan, R.A.; Smith, B.H.; Torrance, N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain 2014, 155, 654–662. [CrossRef] [PubMed]
2. Moulin, D.; Boulanger, A.; Clark, A.J.; Clarke, H.; Dao, T.; Finley, G.A.; Furlan, A.; Gilron, I.; Gordon, A.; Morley-Forster, P.K.; et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 2014, 19, 328–335. [CrossRef]
3. Schaefer, C.; Sadosky, A.; Mann, R.; Daniel, S.; Parsons, B.; Tuchman, M.; Anschel, A.; Stacey, B.R.; Nalamachu, S.; Nieshoff, E. Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study. Clinicoecon. Outcomes. Res. 2014, 6, 483–496. [CrossRef] [PubMed]
4. Du, X.; Gamper, N. Potassium channels in peripheral pain pathways: Expression, function and therapeutic potential. *Curr. Neuropharmacol.* 2013, 11, 621–640. [CrossRef] [PubMed]

5. Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K⁺ channels. *Prog. Biophys. Mol. Biol.* 2003, 81, 133–176. [CrossRef]

6. Qian, L.P.; Shen, S.R.; Chen, J.J.; Ji, L.L.; Cao, S. Peripheral K<sub>ATP</sub> activation inhibits pain sensitization induced by skin/muscle incision and retraction via the nuclear factor-kB/c-Jun N-terminal kinase signaling pathway. *Med. Rep.* 2016, 14, 2632–2638. [CrossRef]

7. Barreras-Espinoza, I.; Soto-Zambrano, J.A.; Serafín-Higuera, N.; Zapata-Morales, R.; Alonso-Castro, Á.; Bologna-Molina, R.; Granados-Soto, V.; Isiodría-Espinoza, M.A. The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K. *Drug Dev. Res.* 2017, 78, 63–70. [CrossRef]

8. Koh, W.U.; Shin, J.W.; Bang, J.Y.; Kim, S.G.; Song, J.G. The Antiallodynic Efficacy of Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K. *Drug Dev. Res.* 2017, 78, 63–70. [CrossRef]

9. Kawano, T.; Zoga, V.; McCallum, J.B.; Wu, H.E.; Gemes, G.; Liang, M.Y.; Abram, S.; Kwok, W.M.; Hogan, Q.; Sarantopoulos, C. ATP-sensitive potassium currents in rat primary afferent neurons: Biophysical, pharmacological properties, and alterations by painful nerve injury. *Neuroscience* 2009, 162, 431–443. [CrossRef]

10. Kawano, T.; Zoga, V.; Kimura, M.; Liang, M.Y.; Wu, H.E.; Gemes, G.; McCallum, J.B.; Kwok, W.M.; Hogan, Q.H.; Sarantopoulos, C.D. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: Action by direct S-nitrosylation. *Mol. Pain* 2009, 5, 12. [CrossRef]

11. Kawano, T.; Zoga, V.; Gemes, G.; McCallum, J.B.; Wu, H.E.; Pravdic, D.; Liang, M.Y.; Kwok, W.M.; Hogan, Q.; Sarantopoulos, C. Suppressed Ca<sup>2+</sup>/CaM/CaMKII-dependent K<sub>ATP</sub> channel activity in primary afferent neurons mediates hyperalgesia after axotomy. *Proc. Natl. Acad. Sci. USA* 2009, 106, 8725–8730. [CrossRef]

12. Zoga, V.; Kawano, T.; Liang, M.Y.; Biennengraeber, M.; Weihrauch, D.; McCallum, B.; Gemes, G.; Hogan, Q.; Sarantopoulos, C. K<sub>ATP</sub> channel subunits in rat dorsal root ganglia: Alterations by painful axotomy. *Mol. Pain* 2010, 6, 6. [CrossRef]

13. Chi, X.X.; Jiang, X.; Nicol, G.D. ATP-sensitive potassium currents reduce the PGE2-mediated enhancement of excitability in adult rat sensory neurons. *Brain Res.* 2007, 1145, 28–40. [CrossRef]

14. Shen, S.; Cao, S.; Huang, S.; Chen, J. Effect of adenosine triphosphate-sensitive potassium activation on peripheral and central pain sensitization. *J. Surg. Res.* 2015, 195, 481–487. [CrossRef]

15. Gregory, N.S.; Harris, A.L.; Robinson, C.R.; Dougherty, P.M.; Fuchs, P.N.; Sluka, K.A. An overview of animal models of pain: Disease models and outcome measures. *J. Pain* 2013, 14, 1255–1269. [CrossRef] [PubMed]

16. Klein, A.H.; Bjork, J.; Entenmann, N.; Jurgenson, T.; Luu, W. Modulation of K<sub>ATP</sub> channel activity in the peripheral nervous system reduces mechanical hyperalgesia after nerve injury. *J. Pain* 2017, 18, SI5. [CrossRef]

17. Seghers, V.; Nakazaki, M.; DeMayo, F.; Aguilar-Bryan, L.; Bryan, J. Sur1 knockout mice. A model for different neuropathic pain syndromes. *J. Biol. Chem.* 2000, 275, 9270–9277. [CrossRef] [PubMed]

18. Wu, X.F.; Liu, W.T.; Liu, Y.P.; Huang, Z.J.; Zhang, Y.K.; Song, X.J. Reopening of ATP-sensitive potassium channels reduces neuropathic pain and regulates astroglial gap junctions in the rat spinal cord. *Pain* 2011, 152, 439–450. [CrossRef] [PubMed]

19. Maier, C.; Baron, R.; Tolle, T.R.; Binder, A.; Birbaumer, N.; Birkenfeld, L.; Gierthmühlen, J.; Flor, H.; Geber, C.; Hug, V.; et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. *Pain* 2010, 150, 129, 79–84. [CrossRef]

20. Lahmann, C.; Clark, R.H.; Iberl, M.; Ashcroft, F.M. A mutation causing increased K<sub>ATP</sub> channel activity leads to reduced anxiety in mice. *Physiol. Behav.* 2014, 129, 79–84. [CrossRef]

21. Wellnitz, S.A.; Lesniak, D.R.; Gerling, G.J.; Lumpkin, E.A. The regularity of sustained firing reveals two populations of slowly adapting touch receptors in mouse hairy skin. *J. Neurophysiol.* 2010, 103, 3378–3388. [CrossRef] [PubMed]

22. Schäfer, A.; Fraccarollo, D.; Pfütsch, S.; Flierl, U.; Vogt, C.; Pfarg, J.; Kobsar, A.; Renné, T.; Eigenthaler, M.; Ertl, G.; et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. *Br. J. Pharmacol.* 2008, 153, 886–893. [CrossRef] [PubMed]
23. Patil, C.S.; Singh, V.P.; Singh, S.; Kulkarni, S.K. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. *Pharmacology 2004*, 72, 190–195. [CrossRef] [PubMed]

24. Jain, N.K.; Patil, C.S.; Singh, A.; Kulkarni, S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. *Brain Res. 2001*, 909, 170–178. [CrossRef]

25. Shimomura, K.; Tusa, M.; Iberl, M.; Brereton, M.F.; Kaizik, S.; Proks, P.; Lahmann, C.; Yaluri, N.; Modi, S.; Huopio, H.; et al. A mouse model of human hyperinsulinism produced by the E1506K mutation in the sulphonylurea receptor SUR1. *Diabetes 2013*, 62, 3797–3806. [CrossRef] [PubMed]

26. Woo, S.K.; Kwon, M.S.; Ivanov, A.; Gerzanich, V.; Simard, J.M. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. *J. Biol. Chem. 2013*, 288, 3655–3667. [CrossRef] [PubMed]

27. Stokum, J.A.; Kwon, M.S.; Woo, S.K.; Tsymbalyuk, O.; Vennekens, R.; Gerzanich, V.; Simard, J.M. SUR1-TRPM4 and AQP4 form a heteromultimeric complex that amplifies ion/water osmotic coupling and drives astrocyte swelling. *Glia 2018*, 66, 108–125. [CrossRef]

28. Tosun, C.; Kurland, D.B.; Mehta, R.; Castellani, R.J.; deJong, J.L.; Kwon, M.S.; Woo, S.K.; Gerzanich, V.; Simard, J.M. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. *Stroke 2013*, 44, 3522–3528. [CrossRef]

29. Mehta, R.I.; Tosun, C.; Ivanova, S.; Tsymbalyuk, N.; Famakin, B.M.; Kwon, M.S.; Castellani, R.J.; Gerzanich, V.; Simard, J.M. SUR1-TRPM4 Cation Channel Expression in Human Cerebral Infarcts. *J. Neuropathol. Exp. Neurol. 2015*, 74, 835–849. [CrossRef]

30. Du, X.; Wang, C.; Zhang, H. Activation of ATP-sensitive potassium channels antagonize nociceptive behavior and hyperexcitability of DRG neurons from rats. *Mol. Pain 2011*, 7, 35. [CrossRef]

31. Niu, K.; Saloman, J.L.; Zhang, Y.; Ro, J.Y. Sex differences in the contribution of ATP-sensitive K+ channels in trigeminal ganglia under an acute muscle pain condition. *Neuroscience 2011*, 180, 344–352. [CrossRef]

32. Afify, E.A.; Khedr, M.M.; Omar, A.G.; Nasser, S.A. The involvement of K_{ATP} in the development and maintenance of neuropathic pain in the rat. *Brain Res. 2011*, 1429, 161–170. [CrossRef]

33. Stokum, J.A.; Kwon, M.S.; Woo, S.K.; Tsymbalyuk, O.; Vennekens, R.; Gerzanich, V.; Simard, J.M. SUR1-TRPM4 and AQP4 form a heteromultimeric complex that amplifies ion/water osmotic coupling and drives astrocyte swelling. *Glia 2018*, 66, 108–125. [CrossRef] [PubMed]

34. Ortega, F.J.; Vukovic, J.; Rodriguez, M.J.; Bartlett, P.F. Blockade of microglial K_{ATP} -channel abrogates suppression of inflammatory-mediated inhibition of neural precursor cells. *Glia 2014*, 62, 247–258. [CrossRef]

35. Truett, G.E.; Heeger, P.; Mynatt, R.L.; Truett, A.A.; Walker, J.A.; Warman, M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). *Biotechniques 2000*, 29, 52–54. [CrossRef] [PubMed]

36. Ye, G.L.; Savelieva, K.V.; Vogel, P.; Baker, K.B.; Mason, S.; Lanthorn, T.H.; Rajan, I. Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit. *Behav. Brain Res. 2015*, 276, 99–110. [CrossRef] [PubMed]

37. Klein, A.H.; Mohammad, H.K.; Ali, R.; Peper, B.; Wilson, S.P.; Raja, S.N.; Ringkamp, M.; Sweitzer, S. Overexpression of μ-Opioid Receptors in Peripheral Afferents, but Not in Combination with Enkephalin, Decreases Neuropathic Pain Behavior and Enhances Opioid Analgesia in Mouse. *Anesthesiology 2018*, 128, 967–983. [CrossRef]

38. Martinov, T.; Mack, M.; Sykes, A.; Chatterjea, D. Measuring changes in tactile sensitivity in the hind paw of mice using an electronic von Frey apparatus. *J. Vis. Exp. 2013*, e51212. [CrossRef]

39. Klein, A.H.; Sawyer, C.M.; Carstens, M.I.; Tsagareli, M.G.; Tsiklauri, N.; Carstens, E. Topical application of L-menthol induces heat analgesia, mechanical allodynia, and a biphasic effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. *Pharmacology 2004*, 72, 190–195. [CrossRef] [PubMed]

40. Röyttä, M.; Wei, H.; Pertovaara, A. Spinal nerve ligation-induced neuropathy in the rat: Sensory disorders and correlation between histology of the peripheral nerves. *Pain 1999*, 80, 161–170. [CrossRef]
43. Alves, D.P.; Tatsuo, M.A.; Leite, R.; Duarte, I.D. Diclofenac-induced peripheral antinociception is associated with ATP-sensitive K+ channels. Br. J. Pharmacol. 2000, 129, 110–114. [CrossRef] [PubMed]

44. Crispim Junior, C.F.; Pederiva, C.N.; Bose, R.C.; Garcia, V.A.; Lino-de-Oliveira, C.; Marino-Neto, J. ETHOWATCHER: Validation of a tool for behavioral and video-tracking analysis in laboratory animals. Comput. Biol. Med. 2012, 42, 257–264. [CrossRef]

45. Maia, J.L.; Lima-Júnior, R.C.; Melo, C.M.; David, J.P.; David, J.M.; Campos, A.R.; Santos, F.A.; Rao, V.S. Oleanolic acid, a pentacyclic triterpene attenuates capsaicin-induced nociception in mice: Possible mechanisms. Pharmacol. Res. 2006, 54, 282–286. [CrossRef]

46. Rodrigues, A.R.A.; Duarte, I.D.G. The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K+ channels. Br. J. Pharmacol. 2000, 129, 110–114. [CrossRef] [PubMed]

47. Ortiz, M.I.; Torres-López, J.E.; Castañeda-Hernández, G.; Rosas, R.; Vidal-Cantú, G.C.; Granados-Soto, V. Pharmacological evidence for the activation of K+ channels by diclofenac. Eur. J. Pharmacol. 2002, 438, 85–91. [CrossRef]

48. Alves, D.P.; Soares, A.C.; Francischì, J.N.; Castro, M.S.; Perez, A.C.; Duarte, I.D. Additive antinociceptive effect of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP. Eur. J. Pharmacol. 2004, 489, 59–65. [CrossRef] [PubMed]

49. Alves, D.P.; Tatsuo, M.A.; Leite, R.; Duarte, I.D. Diclofenac-induced peripheral antinociception is associated with ATP-sensitive K+ channels activation. Life Sci. 2004, 74, 2577–2591. [CrossRef]

50. Klein, A.H.; Sawyer, C.M.; Zanotto, K.L.; Ivanov, M.A.; Cheung, S.; Carstens, M.I.; Furrer, S.; Simons, C.T.; Slack, J.P.; Carstens, E. A tingling sanshool derivative excites primary sensory neurons and elicits nocifensive behavior in rats. J. Neurophysiol. 2011, 105, 1701–1710. [CrossRef]

51. Fairbanks, C.A. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv. Drug Deliv. Rev. 2003, 55, 1007–1041. [CrossRef]

52. Hyliden, J.L.; Wilcox, G.L. Intrathecal morphine in mice: A new technique. Eur. J. Pharmacol. 1980, 67, 313–316. [CrossRef]

53. Hirai, T.; Enomoto, M.; Machida, A.; Yamamoto, M.; Kuwahara, H.; Tajiri, M.; Hirai, Y.; Sotome, S.; Mizusawa, H.; Shinomiya, K.; et al. Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum. Gene Ther. Methods 2012, 23, 119–127. [CrossRef] [PubMed]

54. Pflepsen, K.R.; Peterson, C.D.; Kitto, K.F.; Vulchanova, L.; Wilcox, G.L.; Fairbanks, C.A. Detailed Method for Intrathecal Delivery of Gene Therapeutics by Direct Lumbar Puncture in Mice. Methods Mol. Biol. 2019, 305–312. [CrossRef]

55. Vulchanova, L.; Schuster, D.J.; Belur, L.R.; Riedl, M.S.; Podetz-Pedersen, K.M.; Kitto, K.F.; Wilcox, G.L.; McIvor, R.S.; Fairbanks, C.A. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol. Pain 2010, 6, 31. [CrossRef] [PubMed]

56. Schuster, D.J.; Dykstra, J.A.; Riedl, M.S.; Kitto, K.F.; Honda, C.N.; McIvor, R.S.; Fairbanks, C.A.; Vulchanova, L. Visualization of spinal afferent innervation in the mouse colon by AAV8-mediated GFP expression. Neurogastroenterol. Motil. 2013, 25, e89–e100. [CrossRef] [PubMed]

57. Ringkamp, M.; Tal, M.; Hartke, T.V.; Wooten, M.; McKelvy, A.; Turnquist, B.P.; Guan, Y.; Meyer, R.A.; Raja, S.N. Local loperamide injection reduces mechanosensitivity of rat cutaneous, nociceptive C-fibers. PLoS ONE 2012, 7, e42105. [CrossRef]

58. Zimmermann, K.; Hein, A.; Hager, U.; Kaczmarek, J.S.; Turnquist, B.P.; Clapham, D.E.; Reeh, P.W. Phenotyping sensory nerve endings in vitro in the mouse. Nat. Protoc. 2009, 4, 174–196. [CrossRef]